´ëÇѺÎÀÎÁ¾¾ç¿¬±¸È¸ 2022 KGOG Symposium & Workshop-1st Methodology Wroshop : 2022-08-20±³À°ÀÏÀÚ : 2022-08-20
±³À°Àå¼Ò : À¯±¤»çȦ, ÃÖ´ö°æ°ÀÇ½Ç (°í·Á´ëÇб³ÀÇ°ú´ëÇÐ)
±³À°ÁÖÁ¦ :
2022 KGOG Symposium & Workshop-1st Methodology WroshopÁÖÃÖ±â°ü : ´ëÇѺÎÀÎÁ¾¾çÇÐȸ
½ÃÇà±â°ü(ÁöºÎ/°ú) : ´ëÇѺÎÀÎÁ¾¾ç¿¬±¸È¸
´ã´çÀÚ : ±èÀμ÷
¿¬¶ôó : 02-512-5420
À̸ÞÀÏ :
kiskgog@hanmail.net ±³À°Á¾·ù : »êºÎÀΰú±âŸ
Âü¼®¿¹»óÀοø : 150¸í
Èñ¸ÁÆòÁ¡ : 6Á¡
Áö¿ª :
¼¿ïƯº°½Ã±³À°½Ã°£ : 6 ½Ã°£ 45ºÐ
¼¼ºÎ¼ö°·á : 50,000¿ø
ºñ°í
±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 08-20 À¯±¤»çȦ 09:00~09:15 Overview of enrichment designs ¼Ò°æ¾Æ(°Ç±¹´ëº´¿ø)
±³À°½Ã°£ 08-20 À¯±¤»çȦ 09:15~09:30 Overview of adaptive designs ¹é¹ÎÇö(ÇѸ²´ë¼º½Éº´¿ø)
±³À°½Ã°£ 08-20 À¯±¤»çȦ 09:30~09:45 Overview of master protocols ÀÌ»êÈñ(¿øÁÖ¼¼ºê¶õ½º±âµ¶º´¿ø)
Åä·Ð 08-20 À¯±¤»çȦ 09:45~10:00 Panel Discussion ÃÖöÈÆ, ÇÏÁ¤Àº, À̱ÙÈ£(»ï¼º¼¿ïº´¿ø, ±¹°¡ÀÓ»ó½ÃÇèÁö¿øÀç´Ü, ¼¿ï¼º¸ðº´¿ø)
±³À°½Ã°£ 08-20 À¯±¤»çȦ 10:20~10:40 Gynecologic cancer clinical trials in Japan Keiichi Fujiwara(Saitama Medical University International Medical Center)
±³À°½Ã°£ 08-20 À¯±¤»çȦ 10:40~11:00 DSMB in phase 3 multicenter clinical trial ·ù±Ù¿ø(±¹¸³¾Ï¼¾ÅÍÀ§¾Ï¼¾ÅÍ)
±³À°½Ã°£ 08-20 À¯±¤»çȦ 11:00~11:20 Road to successful clinical trials in KGOG ÀÌÁ¤À±(¼¼ºê¶õ½ºº´¿ø)
±³À°½Ã°£ 08-20 À¯±¤»çȦ 11:20~11:40 Clinical trial of Gynecologic cancer in KROG ¹Ú¿ø(»ï¼º¼¿ïº´¿ø)
Åä·Ð 08-20 À¯±¤»çȦ 11:40~11:55 Panel Discussion ±è¹Î±Ô,¹èÀ縸,¾ö±Ù¿ë(»ï¼ºÃ¢¿øº´¿ø,ÇѾç´ëº´¿ø,ºÐ´ç¼¿ï´ëº´¿ø)
±³À°½Ã°£ 08-20 À¯±¤»çȦ 11:55~12:15 Pegylated Liposomal Doxorubicin(PLD) in Platinum- Sensitive Recurrent Ovarian Cancer ÃÖÇöÁø(Á߾Ӵ뱤¸íº´¿ø)
±³À°½Ã°£ 08-20 À¯±¤»çȦ 12:15~12:35 Pegylated Liposomal Doxorubicin(PLD) and bevacizumab combination for recurrent ovarian cancer Á¤¿ë¿í(°³²Â÷º´¿ø)
±³À°½Ã°£ 08-20 ÃÖ´ö°æ°ÀÇ½Ç 320È£ 11:55~12:15 Why I choose PARPi monotherapy for 1LM Á¶ÇѺ°(°³²¼¼ºê¶õ½ºº´¿ø)
±³À°½Ã°£ 08-20 ÃÖ´ö°æ°ÀÇ½Ç 320È£ 12:15~12:35 Clinical decision-making with or without HRD testing È«¼÷Èñ(¼¿ï¼º¸ðº´¿ø)
±³À°½Ã°£ 08-20 À¯±¤»çȦ 13:35~13:55 Study using real world data ½É½ÂÇõ(°Ç±¹´ëº´¿ø)
±³À°½Ã°£ 08-20 À¯±¤»çȦ 13:55~14:15 Study using public health data ÃÖÈ¿±Ù(ÇѸ²´ë¼º½Éº´¿ø)
±³À°½Ã°£ 08-20 À¯±¤»çȦ 14:30~14:50 6th Ovarian Cancer Consensus Conference (OCCC) Àå¼®ÁØ(¾ÆÁִ뺴¿ø)
±³À°½Ã°£ 08-20 À¯±¤»çȦ 14:50~15:05 Gynecologic Cancer Inter (GCIG) 2022 Á¶Çö¿õ(°í´ë±¸·Îº´¿ø)
±³À°½Ã°£ 08-20 À¯±¤»çȦ 15:05~15:20 American Society of Clinical Oncology (ASCO) 2022 ³ëÁØÈ£(»ï¼º¼¿ïº´¿ø)
Åä·Ð 08-20 À¯±¤»çȦ 15:40~16:00 Panel Discussion ±è»ó¿î, ³ëÀçÈ«,ÀÌ»óÈÆ(¼¼ºê¶õ½ºº´¿ø, ºÐ´ç¼¿ï´ëº´¿ø, ¿ï»ê´ëº´¿ø)
±³À°½Ã°£ 08-20 À¯±¤»çȦ 16:00~16:15 Statistics for retrospective studies and meta-analyses ±èÇöÁ¤(°í·ÁÀÇ´ë)
±³À°½Ã°£ 08-20 À¯±¤»çȦ 16:15~16:30 Multi-Arm Multi-Stage (MAMS) Design in Oncologic Study ÀÌÁ¤º¹(¼¿ï¾Æ»êº´¿ø)
±³À°½Ã°£ 08-20 À¯±¤»çȦ 16:30~16:45 Designs for Randomized Phase II Clinical Trials ³²º´È£(Ç층½º)
Åä·Ð 08-20 À¯±¤»çȦ 16:45~17:00 Panel Discussion À̼ºÁ¾,¼Û¿ëÁß,±è±âµ¿(¼¿ï¼º¸ðº´¿ø,¾ç»êºÎ»ê´ëº´¿ø,ºÐ´ç¼¿ï´ëº´¿ø)